Clinical Trial Results:
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 3-ARM STUDY OF THE EFFICACY AND SAFETY OF 2 DOSES OF LENALIDOMIDE VERSUS PLACEBO IN RED BLOOD CELL (RBC) TRANSFUSION-DEPENDENT SUBJECTS WITH LOW- OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH A DELETION (DEL) 5Q[31] CYTOGENETIC ABNORMALITY
Summary
|
|
EudraCT number |
2005-000454-73 |
Trial protocol |
GB SE DE ES IT BE |
Global completion date |
09 Jul 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
17 Nov 2016
|
First version publication date |
20 Apr 2016
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
CSR Synopsis CC-5013-mds-004-synop-rreport-follow-up |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.